Sangamo Therapeutics Inc (NASDAQ:SGMO) Reports Q2 2025 Earnings: Revenue Misses but Narrower-Than-Expected Loss

Sangamo Therapeutics Inc (NASDAQ:SGMO) reported its second-quarter 2025 financial results, missing revenue estimates but delivering a narrower-than-expected loss per share. The clinical-stage biotech firm posted revenue of $18.31 million, falling short of the consensus estimate of $32.31 million. Meanwhile, the company reported a loss per share of $0.08, better than the anticipated $0.13 loss.

Key Financial Takeaways

• Revenue Miss: Reported $18.31M vs. estimated $32.31M, a shortfall of 43.3%.
• EPS Beat: Posted a loss of $0.08 per share, outperforming the estimated $0.13 loss.
• After-Hours Reaction: Shares dropped ~9% following the earnings release, reflecting investor disappointment over the revenue miss despite the EPS beat.

Market Performance Context

The stock had been relatively stable in recent weeks, with minimal movement over the past month (-4%) and a slight decline over the past two weeks (-19.7%). However, the sharp after-hours drop suggests that the revenue miss is weighing more heavily on investor sentiment than the better-than-expected EPS figure.

Business Highlights from the Press Release

The company highlighted positive topline results from its registrational STAAR study in Fabry disease, with the FDA agreeing that the data—including improvements in mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks—will serve as the primary basis for approval. This marks a significant milestone for Sangamo’s gene therapy candidate, ST-920 (isaralgagene civaparvovec), which is wholly owned by the company.

Forward-Looking Estimates vs. Press Release Outlook

While the press release did not provide specific financial guidance, analyst estimates for the full year 2025 project a loss per share of $0.37 and revenue of $58.55 million. For Q3, expectations are set at a loss of $0.12 per share on $6.53 million in revenue. Given the Q2 revenue miss, investors may be reassessing the company’s ability to meet full-year sales projections.

For a deeper dive into Sangamo’s earnings and future estimates, see the detailed earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.